Literature DB >> 7489979

The natural history of nonalcoholic fatty liver: a follow-up study.

M R Teli1, O F James, A D Burt, M K Bennett, C P Day.   

Abstract

Nonalcohol-induced fatty liver is widely believed to be a benign condition with little or no risk of disease progression. There have been occasional reports of progression to cirrhosis but none in the absence of preexisting fibrosis on the index biopsy specimen even when co-existing hepatitis was present (steatohepatitis). From our histological database (1978 to 1985), we identified 161 patients with fatty liver seen at our institution and traced the case notes of 156. One hundred five patients were initially excluded as having an alcohol-induced cause, and the remaining 51 either were seen in the clinic (37) or had died, in which cases copies of their death certificates were obtained (14). A further 7 patients were excluded after clinic attendance gave evidence of alcohol excess and another 4 after review of their initial biopsy showed the presence of fibrosis or steatohepatitis. The apparent cause of the steatosis in the 40 included patients with strictly nonalcohol-induced pure fatty liver was obesity in 12, diabetes in 4 (1 obese patient), and cachexia associated with extrahepatic malignancy in 6. Four of the remaining 19 had serological evidence of an autoimmune disorder, but none of these had any clinical or histological features of autoimmune liver disease. Nine patients had evidence of hyperlipidemia, 3 of whom were also obese. At a median follow-up of 11 years (7 to 16), 12 of 26 living patients had abnormal results of liver blood tests and had repeat liver biopsies performed. None had progressed to steatohepatitis or cirrhosis; 1 obese patient had developed mild fibrosis 9.8 years after her index biopsy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7489979

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  219 in total

1.  Non-alcoholic steatohepatitis (NASH): why biopsy?

Authors:  A McNair
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

2.  Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Pavel Vladimirovich Korita; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

3.  Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program.

Authors:  Cary H Patt; Hwan Y Yoo; Kourosh Dibadj; John Flynn; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

4.  Worsening of steatosis and fibrosis progression.

Authors:  V Ratziu; M Saboury; T Poynard
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

5.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

Review 6.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

Review 7.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

8.  Fatty liver in H63D homozygotes with hyperferritinemia.

Authors:  Giada Sebastiani; Daniel F Wallace; Susan E Davies; Vasu Kulhalli; Ann P Walker; James S Dooley
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

9.  Long term prognosis of fatty liver: risk of chronic liver disease and death.

Authors:  S Dam-Larsen; M Franzmann; I B Andersen; P Christoffersen; L B Jensen; T I A Sørensen; U Becker; F Bendtsen
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 10.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.